Возможности позитронно-эмиссионной томографии в диагностике первичного и рецидивного рака яичников: обзор литературы

Позитронно-эмиссионная томография (ПЭТ) — современный метод радионуклидной визуализации, который позволяет дополнить диагностический процесс информацией о физиологических и метаболических расстройствах в очагах поражения и уточнить характеристику опухолевого процесса. В статье содержится анализ публикаций, посвященных применению ПЭТ с 18F-фтор- дезоксиглюкозой в различных клинических ситуациях при раке яичников — как с целью выявления заболевания на ранних стадиях, дифференциальной диагностики образований яичников, так и для своевременного обнаружения рецидивов, динамического наблюдения в процессе и после окончания комплексного лечения. Представлены мнения исследователей об ограничениях метода, приводящих к получению ложноположительных и ложноотрицательных заключений.

рак яичников, диагностика, позитронно-эмиссионная томография, 18F-фтордезоксиглюкоза

1. Статистика злокачественных новообразований в России и странах СНГ в 2006 г. Под ред. М.И. Давыдова, Е.М. Акселя. М.: РОНЦ им. Н.Н. Блохина РАМН, 2008.

2. Gadducci A., Tana R., Teti G. at al. Analysis of the pattern of hypersensitivity reactions in patients receiving carboplatin pretreatment for recurrent ovarian cancer. Int J Gynecol Cancer 2008;18(4):615–20.

3. Горелова И.А. Муцинозные опухоли яичников различного потенциала злокачественности. Автореф. дис. ... канд. мед. наук. ГОУ ДПО РМАПО Минздравсоц- развития; НИИ Клинической онкологии

4. РОНЦ им. Н.Н. Блохина РАМН. М., 2008.

5. Cannistra S.A. Cancer of the ovary. N Engl J Med 2004;351:2519–29.

6. Aebi S., Castiglione M. ESMO Guidelines Work- ing Group. Epithelial ovarian carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008;19(2):14–6.

7. Favalli G., Odicino F., Torri V., Pecorelli S. Early stage ovarian cancer: the Italian contribution to clinical research. Int J Gynecol Cancer 2001;11(1):12–9.

8. Thigpen J.T., Herrin V.E. Recent developments in the treatment of recurrent ovarian carcinoma. In: Ovarian cancer. Rubin S.C., Sutton G.P. eds. 2nd edition. Philadelpia—Baltimore—N.Y.: Lippincott Williams Wilkins, 2001.

9. Winter-Roach B., Hooper L., Kitchener H. Systematic review of adjuvant therapy for early stage ovarian cancer. Int J Gynecol Cancer 2003;13:395–404.

10. Чекалова М.А., Поддубная И.В., Мазырко М.А., Синицина М.Е. Место УЗТ при планировании лечения злокачественных эпителиальных опухолей яичников. Совр онкол 2007;9(1).

11. Михайловская Е.М. Возможности совмещенной позитронно-эмиссионной и компьютерной томографии в стадировании колоректального рака. Дис. ... канд. мед. наук. ВМедА им. С.М. Кирова.

12. М., 2006.

13. Рудас М.С., Насникова И.Ю., Матякин Г.Г. Позитронно-эмиссионная томография в клинической практике. Учебно- методическое пособие. М.: Центральная клиническая больница УДП РФ, 2007.

14. Gambhir S., Czernin J., Schwimmer J. at al. A tabulated summary of the FDG–РЕТ literature. J Nucl Med 2001;42(5):1–93.

15. Hubner K.F., McDonald T.W., Niethammer J.G. at al. Assessment of primary and metastatic ovarian cancer by positron emission tomography (PET) using 2-[18F] deoxyglucose. Gynecol Oncol 1993;51:197–204.

16. Schroder W., Zimny M., Rudlowski C. at al. The role of 18-F-flurorodeoxyglucose position imaging tomography 18-F-FGD PET in ovarian carcinoma. Int J Gynecol Cancer 1999;9:117–22.

17. Rieber A., Nüssle K., Stöhr I. at al. Preoperative diagnosis of ovarian tumors with MR imaging: comparison with transvaginal sonography, positron emission tomography, and histologic findings. Am J Roentgenol 2001;177(1):123–9.

18. Grab D., Flock F., Stohr I. at al. Classification of asymptomatic adnexal masses by ultrasound, magnetic resonance imaging, and positron emission tomography. Gynecol Oncol 2000;77:454–9.

19. Kawahara K., Yoshida Y., Kurokawa T. at al. Evaluation of positron emission tomography with tracer 18-fluorodeoxyglucose in addition to magnetic resonance imaging in the diagnosis of ovarian cancer in selected women after ultrasonography. J Comput Assist Tomogr 2004;28:505–16.

20. Moran J.K., Lee H.B., Blaufox M.D. Optimization of urinary FDG excretion during PET Imaging. J Nucl Med 1999;40:1352–7.

21. Williams A.D., Cousins C., Soutter W.P. at al. Detection of pelvic lymph node metastases in gynecologic malignancy. A comparison of CT, MR imaging, and positron emission tomography. Am J Roentgenol 2001;177:343–8.

22. Kurokawa T., Yoshida Y., Kawahara K. at al. Whole-body PET with FDG is useful for following up an ovarian cancer patient with only rising CA125 levels within the normal range. Ann Nucl Med 2002;16:491–3.

23. Picchio M., Sironi S., Messa C. at al. Advanced ovarian carcinoma: usefulness of [(18)F]FDG–PET in combination with CT for lesion detection after primary treatment. J Nucl Med 2003;47:77–84.

24. Pandit-Taskar N. Oncologic imaging in gynecologic malignancies. J Nucl Med 2005; 46(11):1842–50.

25. Israel O., Kuten A. Early detection of cancer recurrence: 18F-FDG PET/CT can make a difference in diagnosis and patient care. J Nucl Med 2007;48(1):28–35.

26. Subhas N., Patel P.V., Pannu H.K. at al. Imaging of pelvic malignancies with in-line FDG PET-CT: case examples and common pitfalls of FDG PET. Radiographics 2005; 25:1031–43.

27. Short S., Hoskin P., Wong W. Ovulation and increased FDG uptake on PET: potential for a false-positive result. Clin Nucl Med 2005; 30:707.

28. Choi S.J., Hyun I.Y. Ovarian F-18 FDG uptake in a premenopausal woman (interesting image). Clin Nucl Med 2006;31(3):161–3.

29. Strauss L.G. Fluorine-18 deoxyglucose and false-positive results: a major problem

30. in the diagnostics of oncological patients. Eur J Nucl Med 1996;23:1409–15.

31. Grab D., Flock F., Stohr I., at al. Classification of asymptomatic adnexal masses by ultrasound, magnetic resonance imaging, and positron emission tomography. Gynecol Oncol 2000;77:454–9.

32. Fenchel S., Grab D., Nuessle K. at al. Asymptomatic adnexal masses: correlation of FDG PET and histopathologic findings. Radiology 2002;223:780–8.

33. Tjalma W.A., Carp L., De Beeck B.O. False-positive positron emission tomographic scan and computed tomography for recurrent vaginal cancer: pitfalls of modern imaging techniques. Gynecol Oncol 2004;92:726–8.

34. Cottrill H.M., Fitzcharles E.K., Modesitt S.C. Рositron emission tomography in a premenopausal asymptomatic woman: a case report of increased ovarian uptake in a benign condition.Int J Gynecol Cancer 2005;15:1127–30.

35. Kim S., Kang K., Roh J. at al. Incidental ovarian 18F-FDG accumulation on PET: correlation with the menstrual cycle. Eur J Nucl Med Mol Imag 2005;32(7):757–63.

36. Lerman H., Metser U., Grisaru D. at al. Normal and abnormal 18F-FDG endometrial and ovarian uptake in pre- and рostmenopausal patients: assessment by PET/ CT. J Nucl Med 2004;45:266–71.

37. Ju W., Kim S.C. Discrepancy between magnetic resonance and 18F-fluorodeoxy- glucose positron emission tomography imaging in a case of borderline ovarian tumor. Int J Gynec Cancer 2007;17(5):1031–3.

38. Jung D.C., Choi H.J., Ju W. at al. Discordant MRI/FDG-PET imaging for the diagnosis of borderline ovarian tumors. Int J Gynec Cancer 2007;18(4):637–41.

39. Kumar R., Chauhan A., Jana S., Dadparvar S. Positron emission tomography in gynecological malignancies. Expert Rev Anticancer Ther 2006;6(7):1033–44.

40. Javitt M.C., Fleischer A.C., Andreotti R.F. at al. Expert panel on women's imaging. Staging and follow-up of ovarian cancer. [Online publication]. Reston (VA): American College of Radiology, 2007.

41. Berger K.L., Nicholson S.A., Dehdashti F., Siegel B.A. FDG-PET evaluation of mucinous neoplasms: correlation of FDG uptake with his-topathologic features. Am J Roentgenol 2000;174:1005–8.

42. Martinez-Roman S., Ramirez P.T., Oh J. at al. Combined positron emission tomography and computed tomography for the detection of recurrent ovarian mucinous adenocarcinoma. Gynecol Oncol 2005;96:888–91.

43. Römer W., Avril N., Dose J. at al. Metabolic characterization of ovarian tumors with positron-emission tomography and F-18 fluorodeoxyglucose. Rofo Fortschr Geb Rontgenstr 1997;166(1):62–8.

44. Yoshida Y., Kurokawa T., Kawahara K. at al. Incremental benefits of FDG positron emission tomography over CT alone for the preoperative staging of ovarian cancer. Am J Roentgenol 2004;182:227–33.

45. Yuan C.C., Liu R.S., Wang P.H. at al. Whole-body PET with (fluorine-18)-2-deoxy- glucose for detecting recurrent ovarian carcinoma: initial report. J Reprod Med 1999;44:775–8.

46. Nakamoto Y., Saga T., Fujii S. at al. Positron emission tomography application for gynecologic tumors. Int J Gynecol Cancer 2005;15(5):701–9.

47. Basu S., Li G., Alavi A. PET and PET-CT imaging of gynecological malignancies: present role and future promise. Expert Rev Anticancer Ther 2009;9(1):75–96.

48. Maffione A.M., Piva M., Tsamita C.S. at al. Positron-emission tomography in gynaecologic malignancies. Arch Gynecol Obstet 2009;280(4):521–8.

49. Lai C.H., Yen T.C., Chang T.C. Positron emission tomography imaging for gynecologic malignancy. Curr Opin Obstet Gynecol 2007; 19(1):37–41.

50. Ghosh J., Kumar L., Thulkar S. at al. Value of 18F-FDG PET-CT scan in the evaluation of recurrent asymptomatic epithelial ovarian cancer patients with rising serum CA-125. J Clin Oncol (Meeting Abstracts) 2008;26(15):16535.

51. Smith G.T., Hubner K.F., McDonald T., Thie J.A. Cost analysis of FDG PET for managing patients with ovarian cancer. Clin Positron Imag 1999;2:63–70.

52. Rose P.G., Faulhaber P., Miraldi F., Abdul-Karim F.W. Positron emission tomography for evaluating a complete clinical response in patients with ovarian or peritoneal carcinoma: correlation with second-look laparotomy. Gynecol Oncol 2001;82:17–21.

53. Kubik-Huch R.A., Dorffler W., von Schulthess G.K. at al. Value of (18F)-FDG positron emission tomography, computed tomography, and magnetic resonance imaging in diagnosing primary and recurrent ovarian carcinoma. Eur Radiol 2000;10:761–7.

54. Yen R.F., Sun S.S., Shen Y.Y. at al. Whole body positron emission tomography with 18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancer. Anticancer Res 2001;21(5):3691–4.

55. Chang W.C., Hung Y.C., Kao C.H. at al. Usefulness of whole body positron emission tomography (FDG-PET) with 18F-fluoro-2- deoxyglucose (FDG) to detect recurrent ovarian cancer based on asymptomatically elevated serum levels of tumor marker. Neoplasma 2002;49:329–33.

56. Torizuka T., Nobezawa S., Kanno T. at al. Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine- 18]-fluoro-2-deoxy-D-glucose. Eur J Nucl Med Mol Imag 2002;29(6):797–803.

57. Garcia Velloso M.J., Boan Garcia J.F., Villar Luque L.M. at al. F-18-FDG positron emission tomography in the diagnosis of ovarian recurrence. Comparison with CT scan and CA 125. Rev Esp Med Nucl 2003;22:217–23.

58. Drieskens O., Stroobants S., Gysen M. at al. Positron emission tomography with FDG in the detection of peritoneal and retroperitoneal metastases of ovarian cancer. Gynecol Obstet Invest 2003;55:130–4.

59. Kim S., Chung J.K., Kang S.B. at al. [18F]FDG PET as a substitute for second-look laparotomy in patients with advanced ovarian carcinoma. Eur J Nucl Med Mol Imag 2004;31:196–201.

60. Bristow R.E., Simpkins F., Pannu H.K. at al. Positron emission tomography for detecting clinically occult surgically resectable metastatic ovarian cancer. Gynecol Oncol 2002;85:196–200.

61. Turlakow A., Yeung H.W., Salmon A.S. at al. Peritoneal carcinomatosis: role of (18) F-FDG PET. J Nucl Med 2003;44:1407–12.

62. Murakami M., Miyamoto T., Iida T. at al. Whole-body positron emission tomography and tumor marker CA125 for detection of recurrence in epithelial ovarian cancer. Int J Gynecol Cancer 2006;16(1):99–107.

63. Menzel C., Dobert N., Hamscho N. at al. The influence of CA 125 and CEA levels on the results of (18)F-deoxyglucose positron emission tomography in suspected recurrence of epithelial ovarian cancer. Strahlenther Onkol 2004;180:497–501.

64. Jiménez-Bonilla J., Maldonado A., Morales S. at al. Clinical impact of 18F-FDG-PET in the suspicion of recurrent ovarian carcinoma based on elevated tumor marker serum levels. Clin Positron Imag 2000; 3(6):231–6.

65. Nakamoto Y., Saga T., Ishimori T. at al. Clinical value of positron emission tomography with FDG for recurrent ovarian cancer. Am J Roentgenol 2001;176(6):1449–54.

66. Delbeke D., Martin W.H. Positron emission tomography imaging in oncology. Radiol Clin North Am 2001;39:883–917.

67. Takekuma M., Maeda M., Ozawa T. at al. Positron emission tomography with 18F-fluoro-2- deoxyglucose for the detection of recurrent ovarian cancer. Int J Clin Oncol 2005;10:177–81.

68. Khan N., Oriuchi N., Yoshizaki A. at al. Diagnostic accuracy of FDG PET imaging for the detection of recurrent or metastatic gynecologic cancer. Ann Nucl Med 2005;19(2):137–45.

69. Ebina Y., Akashi D., Takeda M. at al. Clinical impact of FDG-PET for recurrent ovarian cancer. J Clin Oncol 2004;22(14):5124.

70. Cho S.M., Ha H.K., Byun J.Y. at al. Usefulness of FDG PET for assessment of early recurrent epithelial ovarian cancer. Am J Roentgenol 2002;179(2):391–5.

71. Nanni C., Rubello D., Farsad M. at al. (18)F-FDG PET/CT in the evaluation of recurrent ovarian cancer: a prospective study on forty-one patients. Eur J Surg Oncol 2005; 31:792–7.

72. Gu P., Pan L.L., Wu S.Q. at al. CA 125, PET alone, PET-CT, CT and MRI in diagnosing recurrent ovarian carcinoma: a systematic review and meta-analysis. Eur J Radiol 2009;71(1):164–74.

73. Havrilesky L.J., Kulasingam S.L., Matchar D.B., Myers E.R. FDG-PET for management of cervical and ovarian cancer. Gynecol Oncol 2005;97:183–91.

74. Shibata K., Uno K., Matuso Y. at al. Usefulness and clinical application of FDG PET for assessment of early recurrent epithelial ovarian cancer. J Nucl Med 2006;47(1):225.

75. Yen T.C., Lai C.H. Positron emission tomography in gynecologic cancer. Semin Nucl Med 2006;36:93–104.

76. Sironi S., Messa C., Mangili G. at al. Integrated FDG PET/CT in patients with persistent ovarian cancer: correlation with histologic findings. Radiology 2004; 233:433–40.

77. Wahl R.L. Why Nearly All PET of abdominal and pelvic cancers will be performed as PET/CT. J Nucl Med 2004;45(1):82–95.

78. Barranger E., Kerrou K., Petegnief Y. at al. Laparoscopic resection of occult metastasis using the combination of FDG-positron emission tomography/computed tomography image fusion with intraoperative probe guidance in a woman with recurrent ovarian cancer. Gynecol Oncol 2005;96:241–4.

79. Musto A., Zamagni C., Castellucci P. at al. Early response evaluation to neoadjuvant chemotherapy by FDG PET in patients with advanced ovarian cancer: Preliminary analysis. J Nucl Med 2006;47(1):460.

80. Delgado Bolton R.C., Izarduy L.P., Carreras Delgado J.L. Positron emission tomography and positron emission tomography / computed tomography in the evaluation of response to chemotherapy. Cancer Chemother Rev 2008;3(2):77–86.

81. Zimny M. Ovarian cancer. In: PET and PET-CT in oncology. Oehr P., Biersack H.J., Coleman R.E., eds. Berlin: Springer-Berlag, 2004. Р. 226–35.

82. Avril N., Sassen S., Schmalfeldt B. at al. Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorode- oxyglucose positron emission tomography in patients with advanced-stage ovarian cancer. J Clin Oncol 2005;23(30):7445–53.

83. Nishiyama Y., Yamamoto Y., Kanenishi K. at al. Monitoring the neoadjuvant therapy response in gynecological cancer patients using FDG PET. Eur J Nucl Med Mol Imag 2008; 35(2):287–95.

84. Kurosaki H., Oriuchi N., Okazaki A. at al. Prognostic value of FDG-PET in patients with ovarian carcinoma following surgical treatment. Ann Nucl Med 2006;20(3): 171–4.

85. Messa C., Bettinardi V., Picchio M. at al. PET/CT in diagnostic oncology. Q J Nucl Med Mol Imag 2004;48:66–75.

86. Townsend D.W., Carney J., Yap J.T., Hall N.C. PET/CT today and tomorrow. J Nucl Med 2004;45:4–14.

87. Ben-Haim S., Ell P. 18F-FDG PET and PET/CT in the evaluation of cancer treatment response. J Nucl Med 2009;50(1):88–99.